Get the latest news, insights, and market updates on MRKR (Marker Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
US High Growth Tech Stocks To Watch December 2025
As the United States market navigates a period of volatility, with major indexes closing lower amid concerns over an AI bubble and looming economic reports, investors are keenly observing the tech sector's dynamics. In such a climate, identifying high-growth tech stocks involves looking for companies with strong fundamentals and resilience to market pressures. Dec 17, 2025 - $MRKR
Exploring Three High Growth Tech Stocks In The US Market
Amidst a backdrop of declining major stock indexes, with the S&P 500 and Dow Jones Industrial Average experiencing their fourth consecutive losses due to AI bubble concerns and tepid labor data, the tech-heavy Nasdaq has also seen a recent decline. In this environment, identifying high-growth tech stocks requires careful consideration of companies that demonstrate resilience and potential for innovation despite broader market challenges. Dec 17, 2025 - $MRKR
3 High Growth Tech Stocks To Watch In The US Market
As the U.S. market grapples with fluctuating indices and AI bubble concerns, the Dow Jones Industrial Average recently hit an all-time high before retreating, while tech-heavy stocks like those in the Nasdaq face pressure amid broader economic uncertainties. In this dynamic environment, identifying high-growth tech stocks involves looking for companies that demonstrate resilience and adaptability to market shifts, particularly those that can navigate technological advancements and investor... Dec 15, 2025 - $MRKR
US High Growth Tech Stocks to Watch
The United States market has recently experienced declines in major stock indexes, with technology shares exerting downward pressure on the Nasdaq amid concerns about an AI bubble. In this environment, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation potential and resilience against broader market volatility. Dec 15, 2025 - $MRKR
High Growth Tech Stocks In The US Market With Potential
The U.S. stock market has recently experienced a surge, with major indices like the S&P 500 and the small-cap Russell 2000 reaching near-record highs following the Federal Reserve's decision to cut interest rates. This favorable monetary policy environment can create opportunities for high-growth tech stocks, which often thrive in conditions of lower borrowing costs and increased investor optimism. When considering these stocks, it's important to look for companies with strong innovation... Dec 11, 2025 - $MRKR
High Growth Tech Stocks to Watch in US December 2025
As the U.S. stock market navigates a week marked by anticipation of the Federal Reserve's interest rate decision, major indices such as the S&P 500 have recently pulled back from record highs, reflecting investor caution amidst economic uncertainty. In this context, identifying high-growth tech stocks requires a focus on companies with robust innovation strategies and adaptability to changing market dynamics, which can potentially thrive even in volatile environments. Dec 9, 2025 - $MRKR
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in relapsed Non-Hodgkin lymphoma (NHL) patients in the ongoing APOLLO study First patient treated in Off-the-Shelf program (RAPID study) investigating MAR-T cells in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) cGMP manufacturing collaboration established with Cellipont Bios Nov 14, 2025 - $MRKR
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company’s Board of Directors, effective November 1, 2025. Ms. Penkus Corzo has vast experience as a biopharma executive, drug developer and independent bo Nov 5, 2025 - $MRKR
Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data MT-601 demonstrated robust safety profile with no dose limiting toxicities (DLTs) or immune-effector cell associated neurotoxicity syndrome (ICANS) in the dose escalation cohort HOUSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immuno Nov 3, 2025 - $MRKR
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple